Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of composition of net revenues by payor type and core service lines

The composition of net revenue by payor type for the years ended December 31, 2022, 2021 and 2020 are as follows (in thousands):

	Year Ended December 31,
	2022		2021		2020
Insurance	$	1,808,633	$	1,499,154	$	657,033
Government	781,975		685,513		295,657
Patient pay	379,987		269,868		103,699
Net revenue	$	2,970,595	$	2,454,535	$	1,056,389

The composition of net revenue by core service lines for the years ended December 31, 2022, 2021 and 2020 are as follows (in thousands):

	Year Ended December 31,
	2022		2021		2020
Net sales revenue:
Sleep	$	794,021	$	654,130	$	312,860
Diabetes	670,988		528,082		159,490
Supplies to the home	179,326		167,830		145,624
Respiratory	34,342		31,016		28,605
HME	118,542		113,805		58,029
Other	218,461		144,543		54,689
Total net sales revenue	$	2,015,680	$	1,639,406	$	759,297
Net revenue from fixed monthly equipment reimbursements:
Sleep	$	272,705	$	237,252	$	98,361
Diabetes	16,103		13,123		2,467
Respiratory	520,697		427,270		123,860
HME	102,256		95,936		55,847
Other	43,154		41,548		16,557
Total net revenue from fixed monthly equipment reimbursements	$	954,915	$	815,129	$	297,092
Total net revenue:
Sleep	$	1,066,726	$	891,382	$	411,221
Diabetes	687,091		541,205		161,957
Supplies to the home	179,326		167,830		145,624
Respiratory	555,039		458,286		152,465
HME	220,798		209,741		113,876
Other	261,615		186,091		71,246
Total net revenue	$	2,970,595	$	2,454,535	$	1,056,389

Schedule of carrying amounts and estimated fair values of debt

The table below shows the carrying amounts and estimated fair values, net of unamortized deferred financing costs, of the Company’s long-term debt arrangements (in thousands):

	December 31, 2022				December 31, 2021
	Carrying Value		Fair Value		Carrying Value		Fair Value
Secured term loan	$	761,547	$	761,547	$	780,414	$	780,414
Senior unsecured notes	1,426,720		1,227,574		1,423,138		1,459,137
	$	2,188,267	$	1,989,121	$	2,203,552	$	2,239,551

Summary of cash and cash equivalents

Cash and cash equivalents consist of the following:

	December 31,
(in thousands)	2022		2021
Cash	$	46,272	$	149,613
Money market accounts	—		14
Total	$	46,272	$	149,627

Summary of useful lives of property and equipment for purposes of computing depreciation

The useful lives of property and equipment for purposes of computing depreciation are:

Patient medical equipment	13 months ‑ 5 years
Vehicles	5 years
Other	2 ‑ 10 years

Schedule of useful lives of intangible assets acquired

The following table summarizes the useful lives of the Company's identifiable intangible assets:

Tradenames	5 to 10 years
Payor contracts	10 years
Contractual rental agreements	2 years
Developed technology	5 years

Summary of cost of net revenue

Cost of net revenue for the years ended December 31, 2022, 2021 and 2020 consisted of the following (in thousands):

	Year Ended December 31,
	2022		2021		2020
Cost of products and supplies	$	1,199,481	$	955,813	$	441,931
Salaries, labor and benefits	770,669		595,668		257,898
Patient equipment depreciation	286,288		194,958		71,072
Rent and occupancy	64,375		48,586		22,344
Other operating expenses	225,719		206,599		97,511
Equity-based compensation	6,637		7,301		7,845
Total	$	2,553,169	$	2,008,925	$	898,601